New study tracks arthritis drug persistence in daily life
NCT ID NCT07532226
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study follows 200 adults with psoriatic arthritis who are starting guselkumab as part of their normal care. Researchers will track how many patients continue the treatment after one and two years, and why some stop. The goal is to understand how well the drug works in real-world settings, outside of controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- guselkumab
- What this could lead to
- If successful, this study could show that guselkumab helps many patients with psoriatic arthritis stay on treatment longer, potentially improving disease control.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may vary by patient and may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTHRITIS, PSORIATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital Roger Salengro - CHU Lille
RECRUITINGLille, 59037, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study to measure drug levels in breast milk of moms on TREMFYA
- New drug shows promise in taming psoriatic arthritis flares
- New injection targets psoriatic arthritis pain in small trial
- Scientists probe hidden pain pathways in arthritis
- New drug combo shows promise for Tough-to-Treat psoriatic arthritis
- New psoriatic arthritis drug shows promise in Mid-Stage trial